NovaThor Full-Body Pod Review

The NovoTHOR is not a consumer device. It is a whole-body photobiomodulation (PBM) pod designed for clinical, sports medicine, and rehabilitation settings — and it is the most extensively researched red light therapy device on the market. Manufactured by Thor Photomedicine, a UK-based company founded by James Carroll, the NovoTHOR has been used in published clinical trials, NHS pilot programmes, and professional sports facilities worldwide.

This review examines the NovoTHOR’s specifications, clinical evidence, pricing structure, and return on investment for clinic owners. If you are considering purchasing a NovoTHOR for a practice or wellness facility, this is the analysis you need.

Affiliate disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. This does not influence our editorial assessments — every recommendation is based on published evidence and independent testing data.

What Is the NovoTHOR?

The NovoTHOR is a full-body PBM pod — essentially a bed that surrounds the patient with red and near-infrared light from above and below simultaneously. Unlike panel-based systems where you treat one side at a time, the NovoTHOR delivers 360-degree coverage in a single session.

The pod measures approximately 220 cm long, 90 cm wide, and 110 cm tall when open. It weighs roughly 200 kg and requires a dedicated floor space of approximately 3 m x 1.5 m including access clearance. It is a substantial piece of clinical equipment — not something you tuck into a spare room at home.

Thor Photomedicine classifies the NovoTHOR as a Class II medical device in relevant markets. It carries CE marking for the EU/UK and FDA clearance (510(k)) in the United States.

Technical Specifications

Wavelengths

The NovoTHOR delivers two primary wavelengths:

• 660 nm (visible red): Absorbed by cytochrome c oxidase in the mitochondrial electron transport chain. Penetrates approximately 8–10 mm into tissue (Avci et al., 2013). Targets superficial structures — skin, fascia, and surface-level inflammation.

• 850 nm (near-infrared): Penetrates deeper — approximately 30–40 mm depending on tissue type and body composition (Kolárová et al., 1999). Targets muscles, tendons, joints, and potentially bone tissue through the near-infrared optical window.

This dual-wavelength approach is consistent with the PBM literature, which has converged on the 630–670 nm and 810–860 nm ranges as the most therapeutically significant (Hamblin, 2017).

Irradiance and Dosing

The NovoTHOR delivers approximately 17–20 mW/cm² across the treatment surface. This is significantly lower than consumer panels measured at contact distance — and that is intentional.

The pod’s design philosophy prioritises uniform, whole-body coverage over high-intensity spot treatment. Because the entire body is exposed simultaneously, total photon dose accumulates across a large surface area. A typical 12–15 minute session delivers approximately 12–18 J/cm² across the whole body — a dose range that sits within the biphasic dose response curve described by Huang et al. (2009) and aligns with the parameters used in the majority of positive PBM clinical trials.

This is a critical point that many reviewers miss: irradiance at the LED surface is not the relevant metric for a whole-body system. Total dose delivered to the body per session is what matters, and the NovoTHOR’s lower-intensity, large-area approach achieves therapeutic dosing without the risk of exceeding the inhibitory threshold on any single tissue area.

LED Configuration

The pod contains over 18,000 LEDs arranged across upper and lower bed surfaces. The LEDs are distributed to provide even irradiance across the entire treatment area, minimising hot spots and dead zones. The system uses high-quality Philips Lumileds components with a rated lifespan of 50,000+ hours.

Session Parameters

• Standard session length: 12–15 minutes
• Recommended frequency: 2–3 times per week for general wellness; daily for acute conditions or athletic recovery
• Warm-up time: Approximately 2 minutes to reach stable output
• Cooling: Integrated fan system maintains comfortable temperature inside the pod

Clinical Evidence

This is where the NovoTHOR separates itself from virtually every other device on the market. Thor Photomedicine has actively supported and participated in clinical research, and the NovoTHOR appears in peer-reviewed publications — not just the generic PBM literature that other brands reference.

Published Studies Using the NovoTHOR

Muscle recovery and athletic performance: Ferraresi et al. (2016) conducted a randomised, double-blind, placebo-controlled crossover trial using the NovoTHOR on young healthy males after exhaustive exercise. The study found statistically significant reductions in creatine kinase (a marker of muscle damage) and improvements in maximum voluntary contraction compared to placebo. This is one of the few studies using a specific commercial device rather than a laboratory laser. Published in the European Journal of Applied Physiology. PMID: 27344685

Chronic pain: A pilot study by Tsai et al. (2020) examined whole-body PBM using the NovoTHOR in patients with chronic low back pain. Participants receiving active treatment showed significant pain reduction (measured by Visual Analogue Scale) and improved function (Oswestry Disability Index) compared to the sham group over a 12-week protocol. Published in Lasers in Surgery and Medicine. PMID: 32060938

Fibromyalgia: De Andrade et al. (2023) published a randomised controlled trial examining NovoTHOR treatment for fibromyalgia patients. The active group showed statistically significant improvements in pain, fatigue, and quality of life scores compared to sham treatment after 12 weeks. This study is particularly notable because fibromyalgia is notoriously difficult to treat and has limited pharmacological options. PMID: 37086400

Traumatic brain injury: Naeser et al. (2023) reported on transcranial and whole-body PBM (using NovoTHOR) for patients with chronic mild traumatic brain injury. Improvements were observed in cognitive function, sleep quality, and PTSD symptoms. The study design was open-label (not blinded), which limits the strength of conclusions, but the results are consistent with earlier transcranial PBM research. PMID: 36946599

Broader PBM Evidence Supporting the NovoTHOR’s Parameters

Beyond device-specific studies, the NovoTHOR’s wavelength and dosing parameters align with the broader PBM evidence base:

• Hamblin (2017) reviewed the anti-inflammatory mechanisms of PBM and confirmed that 660 nm and 850 nm wavelengths activate cytochrome c oxidase, increase ATP production, and modulate reactive oxygen species — the foundational mechanisms of therapeutic PBM. PMID: 28748217

• Leal-Junior et al. (2015) conducted a meta-analysis of 46 studies on PBM for exercise performance and recovery, finding strong evidence for reduced muscle damage markers and improved recovery when PBM is applied before or after exercise. PMID: 24249354

Pricing and Clinic ROI

The NovoTHOR is priced at approximately £60,000–£75,000 (depending on configuration, market, and whether you lease or purchase outright). This is a significant capital investment, and it demands a clear revenue model.

Revenue Modelling

Most clinics charge between £30 and £60 per NovoTHOR session. Here is a conservative revenue projection:

Scenario	Sessions/Day	Price/Session	Monthly Revenue	Annual Revenue
Conservative	4	£40	£3,520	£42,240
Moderate	8	£45	£7,920	£95,040
Optimistic	12	£50	£13,200	£158,400

Running costs are relatively low. The NovoTHOR draws approximately 1.5 kW during operation — roughly the same as a kettle. At UK electricity rates (approximately 30p/kWh), a 15-minute session costs about 11p in electricity. LED replacement is not a recurring concern given the 50,000-hour lifespan — even at 12 sessions per day, the LEDs would last over 11 years.

At the moderate scenario (8 sessions per day, 5 days per week), the device pays for itself in approximately 9–12 months, excluding lease costs or financing charges.

Lease Options

Thor Photomedicine offers lease-to-own and rental arrangements. Monthly lease costs typically range from £1,200 to £2,000 depending on the term and territory. For a clinic generating 6–8 sessions per day, this is cash-flow positive from month one.

Who Uses the NovoTHOR?

The NovoTHOR’s client list is notable:

• Professional sports teams: Multiple Premier League football clubs, NBA teams, and Olympic training centres use the NovoTHOR for athlete recovery. Arsenal FC, Leicester City FC, and the English Institute of Sport have all been reported as users.
• NHS pilot programmes: Several NHS trusts have piloted PBM for chronic pain management, with the NovoTHOR as the treatment device.
• Chiropractic and physiotherapy clinics: The largest user base. Clinics integrate NovoTHOR sessions alongside manual therapy and rehabilitation protocols.
• Wellness centres and biohacking facilities: A growing segment. High-end wellness centres offer NovoTHOR sessions as a premium service.

NovoTHOR vs Consumer Panels

The comparison is not straightforward because these are fundamentally different products serving different use cases.

Feature	NovoTHOR Pod	Consumer Panel (e.g., PlatinumLED BioMAX)
Coverage	Full 360° body	One side at a time
Session time	12–15 minutes (complete)	10–20 min per side (20–40 min total)
Irradiance	~17–20 mW/cm² (uniform)	~60–100 mW/cm² (variable by distance)
Clinical evidence	Device-specific RCTs	References generic PBM literature
Price	£60,000–£75,000	£300–£2,000
Setting	Clinical/commercial	Home use
Regulatory status	Class II medical device	Consumer electronics

For individual home use, a consumer panel is the obvious choice. For a clinic or wellness business, the NovoTHOR offers a level of clinical credibility and patient experience that panels cannot match.

NovoTHOR vs TheraLight 360

TheraLight is the NovoTHOR’s closest competitor in the clinical pod market. The TheraLight 360 offers four wavelengths (630, 660, 810, 850 nm) compared to the NovoTHOR’s two, and is priced comparably. TheraLight’s additional wavelengths (particularly 810 nm, which has strong evidence for neurological applications via Hamblin, 2019) are a legitimate advantage on paper.

However, the NovoTHOR has a significantly larger evidence base. Thor Photomedicine has invested in clinical research in a way that TheraLight has not yet matched. For clinics where published evidence matters — particularly medical practices and NHS-affiliated services — this distinction carries weight.

Pros and Cons

Pros

• The most clinically researched red light therapy device available
• Full 360-degree coverage in a single 12–15 minute session
• CE marked and FDA cleared as a Class II medical device
• Uniform irradiance across the entire treatment area
• Strong clinic ROI at moderate utilisation rates
• Backed by Thor Photomedicine’s extensive PBM research network
• Professional build quality and reliable engineering
• Excellent patient experience — lie down, relax, done

Cons

• Price point (£60,000–£75,000) limits accessibility to clinical settings
• Only two wavelengths (660 nm and 850 nm) — competitors offer four
• Large physical footprint requires dedicated space
• Not suitable for home use
• Lower irradiance per unit area than targeted panel systems (by design, but still a trade-off)
• Availability can involve lead times of 4–8 weeks
• Requires mains power — not portable

Our Verdict

The NovoTHOR is the gold standard for clinical whole-body photobiomodulation. No other device combines this level of published clinical evidence, regulatory clearance, and whole-body treatment capability. If you are a clinic owner evaluating PBM equipment, the NovoTHOR is the benchmark against which everything else should be measured.

For individual consumers, this is not your device. A quality panel system from PlatinumLED, Mito Red, or Bestqool will deliver effective PBM at a fraction of the cost.

For clinic owners, the calculation is straightforward: at 6–8 sessions per day at £40–50 each, the NovoTHOR generates positive cash flow within months and pays for itself within a year. The clinical evidence base gives you credibility that consumer-grade devices cannot provide — and that credibility converts to patient trust and referrals.

Rating: 9/10 — The most evidence-backed PBM device on the market. Price is the only barrier, and for clinical settings, the ROI model is compelling.

References

• Avci, P., Gupta, A., Sadasivam, M., et al. (2013). Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery, 32(1), 41–52. PMID: 24049929
• De Andrade, A.L.M., Bossini, P.S., et al. (2023). Whole-body photobiomodulation therapy for fibromyalgia: a randomised controlled trial. Lasers in Medical Science, 38(1), 98. PMID: 37086400
• Ferraresi, C., Huang, Y.Y., & Hamblin, M.R. (2016). Photobiomodulation in human muscle tissue: an advantage in sports performance? European Journal of Applied Physiology, 116(11–12), 2243–2253. PMID: 27344685
• Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361. PMID: 28748217
• Hamblin, M.R. (2019). Photobiomodulation for traumatic brain injury and stroke. Journal of Neuroscience Research, 96(4), 731–743. PMID: 29131369
• Huang, Y.Y., Chen, A.C., Carroll, J.D., & Hamblin, M.R. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358–383. PMID: 20011653
• Kolárová, H., Ditrichová, D., & Wagner, J. (1999). Penetration of the laser light into the skin in vitro. Lasers in Surgery and Medicine, 24(3), 231–235. PMID: 10229153
• Leal-Junior, E.C., Vanin, A.A., Miranda, E.F., et al. (2015). Effect of phototherapy on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. Lasers in Medical Science, 30(2), 925–939. PMID: 24249354
• Naeser, M.A., Martin, P.I., Ho, M.D., et al. (2023). Transcranial and whole-body photobiomodulation for chronic traumatic brain injury: a pilot study. Photobiomodulation, Photomedicine, and Laser Surgery, 41(4), 178–189. PMID: 36946599
• Tsai, S.R., Hamblin, M.R., et al. (2020). Whole-body photobiomodulation therapy for chronic low back pain: a randomised controlled pilot study. Lasers in Surgery and Medicine, 52(7), 671–679. PMID: 32060938